13F Holdings
中文EN

SYRE Spyre Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1636282 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-77.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-35.0%
ROA-32.9%
ROIC (approx.)-29.1%
Asset turnover—

Leverage & solvency

Liabilities / assets4.4%
Debt / equity0.00x
Current ratio27.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0$886,000$2.33M$18.74M
R&D expense$171.65M$162.79M$89.50M$58.58M$57.07M
SG&A expense$47.91M$45.78M$39.95M$28.53M$27.32M
Operating income-$209.56M-$208.57M-$242.30M-$84.78M-$65.65M
Pretax income-$155.22M-$207.97M-$338.82M-$83.95M-$65.66M
Income tax-$15,000$51,000-$26,000-$136,000$141,000
Net income-$155.20M-$208.02M-$338.79M-$83.81M-$65.80M
EBITDA-$209.56M-$208.57M-$241.56M-$83.21M-$64.07M
EPS (basic)——13.76-24.86-25.02
EPS (diluted)——13.76-24.86-25.02
Weighted avg. shares (diluted)——6.90M3.37M2.63M
Balance sheet
Cash & equivalents$85.72M$89.42M$188.89M$36.42M$16.98M
Short-term investments$670.81M$513.66M$150.38M$20.85M$77.99M
Current assets$777.78M$608.47M$341.53M$62.26M$98.89M
PP&E, net——$0$3.22M$4.55M
Total assets$777.78M$608.48M$341.86M$71.14M$109.93M
Current liabilities$58.69M$54.06M$31.98M$14.66M$20.14M
Total liabilities$62.55M$90.68M$73.29M$20.84M$25.98M
Shareholders' equity$715.24M$517.80M$184.02M$50.30M$83.94M
Shares outstanding78.19M60.26M36.06M2.61M49.36M
Cash flow statement
Operating cash flow-$169.25M-$157.41M-$99.91M-$80.14M-$53.72M
Capital expenditure—$0$0$38,000$573,000
Free cash flow—-$157.41M-$99.91M-$80.18M-$54.29M
Investing cash flow-$143.47M-$353.29M-$108.39M$57.01M-$22.62M
Financing cash flow$309.02M$410.91M$361.08M$42.68M$1.39M
Depreciation & amortization$0$0$744,000$1.57M$1.58M
Stock-based compensation$37.61M$44.83M$25.68M$7.11M$8.04M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.